Medtronic: Fairly Valued on Aligned EPS Guidance and Higher Interest Costs, Justifying a Hold Rating
I'm PortAI, I can summarize articles.
William Blair analyst Brandon Vazquez maintains a Hold rating on Medtronic (MDT) stock, citing aligned EPS guidance and higher interest costs. Vazquez's updated financial model reflects limited near-term upside, with revenue projections unchanged and interest expense assumptions revised upward. Truist Financial also maintains a Hold rating with a $107 price target, indicating the stock is fairly valued relative to its earnings outlook and current guidance.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments